

## Research Paper

# Solubility, Stability, Physicochemical Characteristics and *In Vitro* Ocular Tissue Permeability of Hesperidin: A Natural Bioflavonoid

Soumyajit Majumdar<sup>1,2,3</sup> and Ramesh Srirangam<sup>1</sup>

Received April 30, 2008; accepted September 11, 2008; published online September 23, 2008

**Purpose.** Hesperidin holds potential in treating age-related macular degeneration, cataract and diabetic retinopathy. The aim of this study, constituting the first step towards efficient ocular delivery of hesperidin, was to determine its physicochemical properties and *in vitro* ocular tissue permeability.

**Methods.** pH dependent aqueous solubility and stability were investigated following standard protocols. Permeability of hesperidin across excised rabbit cornea, sclera, and sclera plus retinal pigmented epithelium (RPE) was determined using a side-by-side diffusion apparatus.

**Results.** Hesperidin demonstrated poor, pH independent, aqueous solubility. Solubility improved dramatically in the presence of 2-hydroxypropyl-beta-cyclodextrin (HP- $\beta$ -CD) and the results supported 1:1 complex formation. Solutions were stable in the pH and temperature (25, 40°C) conditions tested, except for samples stored at pH 9. Transcorneal permeability in the apical-basal and basal-apical directions was  $1.11 \pm 0.86 \times 10^{-6}$  and  $1.16 \pm 0.05 \times 10^{-6}$  cm/s, respectively. The scleral tissue was more permeable ( $10.2 \pm 2.1 \times 10^{-6}$  cm/s). However, permeability across sclera/choroid/RPE in the sclera to retina and retina to sclera direction was  $0.82 \pm 0.69 \times 10^{-6}$ ,  $1.52 \pm 0.78 \times 10^{-6}$  cm/s, respectively, demonstrating the barrier properties of the RPE.

**Conclusion.** Our results suggest that stable ophthalmic solutions of hesperidin can be prepared and that hesperidin can efficiently permeate across the corneal tissue. Further investigation into its penetration into the back-of-the eye ocular tissues is warranted.

**KEY WORDS:** hesperetin; hesperidin; ocular; permeability; solubility.

## INTRODUCTION

Recently, it has been reported that among non-institutionalized American adults, 18 years or older, prevalence of visual impairment is 9.3%, including 0.3% with blindness (1). The major eye diseases like cataract, glaucoma, macular degeneration and diabetic retinopathy, are supposedly the leading causes. Pathophysiology of diabetic retinopathy involves the process of physiological or pathological angiogenesis. Oxidative damage to the retinal neuronal cells as a result of free radical generation, a complication associated with diabetes, is considered to be a principal factor responsible for the initiation and progression of diabetic retinopathy (2). Decreased retinal blood supply, as a consequence of long term diabetes is another major contributor to the progression of this disease. In patients with diabetes, proliferative diabetic retinopathy is the neovascular result wherein ischemia induced angiogenesis on the surface of the retina, and into the vitreous, is postulated to occur. Increased permeability in these vessels


can lead to diabetic macular edema, the major factor responsible for vision loss (2).

Hesperidin (hesperetin 7-rutinoside) is a flavanone glycoside, comprising of an aglycone, hesperetin, and an attached disaccharide, rutinose. The structures of hesperidin and hesperetin are illustrated in Fig. 1. Hesperidin is abundantly found in citrus fruits (family *Rutaceae*) and has also been reported to occur in many plants other than Citrus, such as in genera *Fabaceae*, *Betulaceae*, *Laminaceae* and *Papilionaceae*. What makes hesperidin, and hesperetin, particularly attractive for the treatment of diabetic retinopathy or macular degeneration is their potential effect on ocular blood flow and vascular permeability, two important factors leading to the initiation and progression of diabetic retinopathy. It has been demonstrated that these compounds can support retinal function recovery subsequent to retinal ischemia (3). Hesperidin's effect on ocular blood vessels has not been studied. However, this compound was initially referred to as 'Vitamin P' to indicate that it could decrease capillary permeability and fragility, although subsequently the term vitamin P has been discontinued (4). Literature reports suggest that hesperidin can prevent microvascular leakage by virtue of its vasoprotective action through the inhibition of the enzyme hyaluronidase which is reported to regulate the permeability of capillary walls and supporting tissues (5). Additionally, it has been demonstrated that hesperidin can decrease blood cell and platelet aggregation,

<sup>1</sup>Department of Pharmaceutics, School of Pharmacy, The University of Mississippi, 111 Faser Hall, University, Mississippi 38677, USA.

<sup>2</sup>Research Institute of Pharmaceutical Sciences, The University of Mississippi, University, Mississippi 38677, USA.

<sup>3</sup>To whom correspondence should be addressed. (e-mail: majumso@olemiss.edu)



**Fig. 1.** **A** and **B** represents chemical structure of hesperidin (hesperetin—7-rhamnoglucoside) and hesperetin (3', 5,7-trihydroxy-4'-methoxy flavanone), respectively.

believed to be beneficial in cases of capillary permeability and fragility (4).

Besides their effect on vascular permeability and ocular blood flow, both hesperidin and hesperetin demonstrate strong antioxidant properties (6). This antioxidant activity is through their ability to quench oxidative radical chain reactions (capable of oxidizing and nitrating cellular proteins, nucleic acids, and lipids), and can thus help preserve neuronal health. Hesperidin also exhibits significant anti-inflammatory activity by modulating the prostaglandin synthesis and COX-2 gene expression pathways (7). Ayalasomayajula *et al.* (8) reported that, in diabetic rat retina, up-regulation of COX-2 is responsible for production of prostaglandin E<sub>2</sub>, a pro-angiogenic factor implicated in vascular permeability and leakage. This prostaglandin up-regulation was inhibited by celecoxib (8), a selective COX-2 inhibitor.

Hesperidin has been reported to possess analgesic (9), hypolipidemic (10), anti-hypertensive and diuretic activity (11). Another potential therapeutic application of hesperidin is its anticancer activity mediated through the suppression of cell proliferation (12,13). Thus, both hesperidin and its metabolite hesperetin, appear to be capable of modulating multiple pathways (Fig. 2) identified in the genesis and progression of diabetic retinopathy and diabetic macular edema. It can also be used in other ocular diseases because of its varied pharmacological actions.

Currently hesperidin is used as a dietary supplement for improving blood flow and for its vasoprotective properties, and is available as an oral dosage form. Ameer *et al.* (14) reported that following oral administration, hesperidin is absorbed across the gastrointestinal tract, but cumulative urinary recovery indicates low bioavailability (<25%). Several factors limit oral bioavailability of hesperidin, including poor water solubility and precipitation in an acidic environment (15). Moreover, hesperidin and hesperetin are substrates of the intestinal efflux protein, P-glycoprotein (P-gp), (16–18) and intestinal and hepatic drug metabolizing enzymes CYP450 (19). These factors, acting together, severely restrict systemic bioavailability of the orally administered drug. Furthermore, hesperidin possesses poor transmembrane permeability and is believed to be absorbed primarily by the paracellular pathway (20,21). Thus intestinal tight junction

proteins would limit intestinal absorption. Additionally, reports indicate that hesperidin needs to be converted to hesperetin, by the beta-glycosidases secreted by the intestinal flora (22), for absorption to occur.

Over and above all the barriers to oral bioavailability, in order to exert a therapeutic effect in diabetic retinopathy, hesperidin must penetrate into the neural retina from the systemic circulation. For this, it needs to permeate across the blood-retinal barrier (BRB), formed by retinal pigmented epithelium (RPE) and endothelial cells of retinal blood vessels. The diffusion limiting capabilities of the BRB has been well established for both hydrophilic (limited by tight junctions) as well as lipophilic (through efflux mechanism) compounds. Thus, following oral administration very little, if any, amounts of hesperidin can reach the neural retina.

The long term goal of this project is to achieve therapeutically optimal hesperidin concentrations at the target site, i.e. posterior segment of the eye. Considering the barriers encountered in oral/systemic administration, topical instillation may be an attractive alternative for producing therapeutic hesperidin levels at the active site. Some other possible routes/modes of administration for achieving higher drug concentrations in the retina include intravitreal injection and implants. However, these are invasive techniques and are associated with side-effects such as retinal detachment and endophthalmitis.


For a topically administered drug, penetration into the posterior chamber tissues, such as the RPE, may be through corneal or noncorneal routes. Transcorneal absorption represents the major route of penetration for most therapeutic agents. However, several studies demonstrate that the non-corneal route is also a significant route, wherein the drug molecule is supposed to penetrate into the intraocular tissues via diffusion across the conjunctiva and sclera (23).

Thus, the objective of this project, constituting the first step towards efficient ocular delivery of hesperidin, was to determine hesperidin's solubility, stability, physicochemical properties and *in vitro* permeability across the ocular tissues—cornea, sclera and RPE.

## MATERIALS AND METHODS

### Materials

Hesperidin, hesperetin and 2-hydroxypropyl beta cyclodextrin (HP- $\beta$ -CD) (1,300 MW 0.6 substitution) were purchased from Sigma-Aldrich (St. Louis, MO, USA). [<sup>14</sup>C] mannitol was purchased from American Radiolabelled Chemicals Inc. (St. Louis, MO, USA) and [<sup>3</sup>H]diazepam



**Fig. 2.** Schematic representation of some of the currently identified pathways involved in the development and progression of diabetic retinopathy and macular degeneration. Asterisk indicates pathways which hesperidin and hesperetin can potentially inhibit.

was obtained from PerkinElmer Life and Analytical Sciences (Boston, MA, USA). All other chemicals and solvents were obtained from Fisher Scientific, USA.

### Ocular Tissues

Ocular tissues were isolated from euthanized adult male New Zealand albino rabbits weighing between 2 and 2.5 kg (Myrtle's Rabbitry, Thompson Station, TN, USA). Experiments using rabbits conformed to the tenets of the Association for Research in Vision and Ophthalmology statement on the Use of Animals in Ophthalmic and Vision Research. Each experiment was conducted at least in quadruplicates.

### Solubility Studies

Aqueous solubility of hesperidin was determined following standard shake flask method wherein excess quantity of drug was added to 5 mL of solvent in a tightly capped glass vial. To achieve uniform mixing, samples were constantly agitated at 75 rpm at room temperature (25°C) for 24 h in a reciprocating water bath (Fisher Scientific, USA). At the end of 24 h, samples were centrifuged (AccuSpin 17R, Fisher Scientific, USA) and the supernatant was analyzed for drug content. Solubility was determined in water and in buffers with pH values ranging between 1.2 and 9. Additionally, effect of surfactants and HP- $\beta$ -CD on the solubility of hesperidin, was also evaluated. HP- $\beta$ -CD concentrations used for the phase solubility studies were 1, 2.5, 5, 7.5, 10, 15 and 20% w/v in water.

### Differential Scanning Calorimetry (DSC) Studies

DSC analysis of hesperidin, HP- $\beta$ -CD, physical mixture of hesperidin and HP- $\beta$ -CD (1:1 molar ratio) and the complex were carried out using a Diamond Differential Scanning Calorimeter (PerkinElmer Life and Analytical Sciences, Shelton, CT, USA). Samples, 2–3 mg, were heated in a hermetically sealed aluminium pans at a heating rate of 10°C/min (25–280°C range) under a nitrogen atmosphere (flow rate 20 mL/min). An empty aluminium pan was used as the reference.

### Fourier Transform Infrared Spectroscopy (FTIR) Studies

FTIR spectra were obtained using a Perkin Elmer FTIR spectrometer (PerkinElmer Life and Analytical Sciences, Shelton, CT, USA). Samples were mixed with dry crystalline KBr in a 1:100 (sample: KBr) ratio and pellets were prepared. A spectrum was collected for each sample within the wave number region 4,000–400 cm<sup>-1</sup>.

### Log *P*

Predicted value of Log *P* was obtained using the ACD/ILab web service (ACD/Log *P* 8.02).

### pH Stability

Solution stability of hesperidin was determined at various pH (1.2, 3, 5, 7.4, and 9) and temperature (25°C and 40°C) conditions. Buffers were prepared according to USP. Stability studies were initiated with the addition of 25  $\mu$ L of a

1 mg/mL hesperidin stock solution to 5 mL of the respective buffer previously equilibrated to either 25°C or 40°C. Aliquots (200  $\mu$ L) were collected at 0, 0.5, 1, 2, 3, 4, 5, 6, 7, 14, 30 and 60 days and were stored at -80°C until further analysis. Samples were analyzed using HPLC technique as described under the analytical method section.


### Stability in Ocular Tissue Homogenates

Ocular tissues isolated from New Zealand albino rabbits were used for the metabolism studies. Animals were euthanized with an overdose of pentobarbital administered through the marginal ear vein. Eyes were enucleated immediately and washed with ice-cold Dulbecco's Phosphate Buffered Saline (DPBS pH 7.4) to remove traces of blood. Vitreous humor was collected through an incision in the sclera. Sclera was isolated with the retinal pigmented epithelium (RPE) attached. The RPE/choroid section was then carefully separated from underlying sclera. This procedure takes approximately 10–15 min. The pooled RPE/choroid tissue was homogenized (TISSUMISER, Fisher Scientific, USA) in 2 mL ice-cold Isotonic Phosphate Buffer Saline (IPBS), pH 7.4, and then centrifuged at 4°C (accuSpin 17R, Fisher Scientific, USA). Supernatant was collected and estimated for total protein content by the method of Bradford (Sigma-Aldrich, USA) (24). Final protein concentration was adjusted to 1 mg/mL by diluting with IPBS and used for the hydrolysis studies. Vitreous humor was used as such without any dilution or homogenization.

Reactions were initiated by adding 20  $\mu$ L of drug solution (1 mg/mL) to 2 mL of the supernatant. The reactions were carried out in a water bath at 37°C. Samples (100  $\mu$ L) were withdrawn at predetermined time intervals and the enzymatic degradation process was arrested with the addition of an equal volume of ice-cold methanol/acetonitrile mixture (60:40). Rate of hydrolysis in IPBS pH 7.4 at 37°C was used as a control. Samples were analyzed using an HPLC technique as described under the analytical method section. Experiments were carried out in triplicate.

### Corneal Permeation Studies

Permeation of hesperidin was studied using a side-by-side diffusion apparatus (PermeGear, Inc.). Corneas isolated from New Zealand Albino male rabbits were used for these studies. Rabbits were euthanized, and eyes were collected as described earlier. Cornea was isolated with a ring of sclera around it, which helps in mounting between diffusion cells. Corneas were washed in DPBS and mounted on the side-by-side diffusion apparatus (standard 9 mm cells were used) (Fig. 3A) with the epithelial side facing the donor cell for apical to basolateral transport (A–B), and with the endothelial side facing the donor cell for basolateral to apical transport (B–A). Temperature of the cells was maintained at 34°C with the help of a circulating water bath. In all cases, 3 mL of transport buffer (DPBS containing 5% HP- $\beta$ -CD) or drug solution (150  $\mu$ M of hesperidin in DPBS with 5% HP- $\beta$ -CD) was added to the apical side of the cornea while 3.2 mL was added to the basal side, to maintain the natural hydrostatic pressure. Aliquots (200  $\mu$ L) were removed at predetermined time points (15, 30, 45, 60, 90, 120, 150 and



**Fig. 3.** Illustration depicting mounting of ocular tissue on regular side-bi-side diffusion cells (A) and on Valia-Chain side-bi-side diffusion cells (B).

180 min) from the receiver side and the volume withdrawn was replaced with an equal volume of transport buffer. Samples were stored at  $-80^{\circ}\text{C}$  until further analysis.

Similar procedures were followed to determine transcorneal permeability of [ $^{14}\text{C}$ ]mannitol (55 mCi/mmol) and [ $^3\text{H}$ ]diazepam (70 mCi/mmol), both at  $0.5 \mu\text{Ci/mL}$  concentration. Five milliliters of scintillation cocktail (Fisher Scientific, USA) was added to each sample and radioactivity was measured using Liquid Scintillation Analyzer (PerkinElmer Life and Analytical Sciences, Model Tri-Carb 2900TR, Shelton, CT, USA).

### Permeation Across Sclera and Retinal Pigmented Epithelium (RPE)

Transscleral permeation studies were carried out using the 5 mm diameter Valia-Chain side-bi-side diffusion cells from PermeGear, Inc (Fig. 3B). After carefully isolating sclera alone, or sclera with RPE/choroid, the tissues were mounted in a manner such that outer surface of the sclera, known as the episclera, faced the donor side (Fig. 3B; half-cell a) and the inner side of sclera, or the RPE side, faced the receiver chamber (Fig. 3B half-cell b) for the transport studies in the sclera to choroid/RPE direction (S to R direction). Donor solution was added to the RPE/choroid side (Fig. 3B half-cell b) for transport in the RPE/choroid to scleral direction (R to S direction). Temperature of the cells was maintained at  $37^{\circ}\text{C}$  with the help of a circulating water bath.  $150 \mu\text{M}$  of hesperidin in DPBS with 5% HP- $\beta$ -CD was placed in donor chamber and DPBS with 5% HP- $\beta$ -CD was placed in receiver chamber. Aliquots ( $200 \mu\text{L}$ ) were removed at predetermined time points (15, 30, 45, 60, 90, 120, 150 and 180 min) from the receiver side and replaced with an equal volume of transport buffer. Samples were stored at  $-80^{\circ}\text{C}$  until further analysis.

Similar procedures were followed to determine permeability of [ $^{14}\text{C}$ ]mannitol (55 mCi/mmol) and [ $^3\text{H}$ ]diazepam (70 mCi/mmol), both at  $0.5 \mu\text{Ci/mL}$  concentration, across sclera/choroid/RPE. Five milliliters of scintillation cocktail (Fisher Scientific, USA) was added to each sample and radioactivity was measured using liquid scintillation analyzer.

### Analytical Method

Hesperidin content in samples collected from the solubility, stability and permeability studies was estimated using

an analytical method based on reversed phase HPLC. An HPLC system equipped with Waters 600 pump controller, 2470 dual wavelength UV detector, refrigerated 717 plus auto-sampler and Agilent 3394B integrator was used. The detector was operated at 284 nm. Mobile phase consisted of 20 mM monobasic potassium phosphate (pH adjusted to 2.5 with orthophosphoric acid) and acetonitrile in a ratio of 75:25 and flow rate was maintained at 1 mL/min. A Waters Symmetry Shield C18 column was used.

Analytical method for the determination of hesperetin content was also developed. The method for hesperetin was similar to that for hesperidin, except for the mobile phase, which, in this case, was a 50:50 mixture of acetonitrile and 20 mM monobasic potassium phosphate (pH adjusted to 2.5 with orthophosphoric acid).

### DATA ANALYSIS

Cumulative amount ( $M_n$ ) transported was calculated using Eq. 1 and steady state (SS) fluxes ( $\mu\text{g min}^{-1} \text{cm}^{-2}$ ) were determined from the slope of the cumulative amount of drug transported vs. time graph and expressed as per unit of surface area as described by Eq. 2.

$$M_n = V_r C_{r(n)} + \sum_{x=1}^{x=n} V_s C_{r(x-1)} \quad (1)$$

$$\text{Flux}(J) = \frac{(dM/dt)}{A} \quad (2)$$

Where,  $M_n$  is the cumulative amount of the drug in the receiver chamber at  $n$ th sampling time point ( $n=1, 2, 3, 4, 5, 6, 7$  and  $8$  corresponding to 15, 30, 45, 60, 90, 120, 150 and 180 min sampling points),  $V_r$  is the volume of the medium in the receiver chamber,  $V_s$  is the volume of the sample withdrawn at the  $n$ th time point,  $C_{r(n)}$  is the concentration of the drug in the receiver chamber medium at  $n$ th time point,  $A$  is the surface area of the tissue exposed to the permeant (surface area of cornea and sclera/RPE exposed is  $0.636$  and  $0.192 \text{ cm}^2$ , respectively). Note that when  $n=1$ , the second part of the right hand side of Eq. 1 becomes zero since concentration in the receiver chamber,  $C_r$ , is zero at time zero.

Membrane permeability (cm/s) values were determined by normalizing the steady state fluxes to the donor concentration,  $C_d$  according to Eq. 3.

$$\text{Permeability}(P_{\text{app}}) = \text{Flux}/C_d \quad (3)$$

### STATISTICAL ANALYSIS

All experiments were carried out at least in triplicate. Unpaired  $t$  test and ANOVA was used for statistical analysis. In all the cases a  $p$  value less than 0.05 was considered to denote statistically significant difference.

### RESULTS AND DISCUSSION


Diabetic retinopathy and macular edema are serious sight threatening conditions. While involvement of several

mechanisms in the pathogenesis of this disease has been suggested, a drug candidate capable of blocking multiple pathways remains to be identified, as yet. Current treatment options, apart from controlling blood glucose and lipid levels, include corticosteroids, anti-vascular endothelial growth factor, laser photocoagulation, and vitrectomy. However, long term treatment with these drugs is associated with toxicity and corticosteroids may lead to cataract formation and increased intraocular pressure (25). Hesperidin appears to modulate multiple pathways associated with diabetic retinopathy and macular edema (Fig. 2) but a suitable ocular delivery mechanism is lacking. In this study, feasibility of developing an ophthalmic solution dosage form of hesperidin was investigated

Solubility is an important factor affecting drug permeability across biological membranes. Solubility of hesperidin in different pH buffers and in water is presented in Table I. The compound was observed to be very poorly soluble in water and exhibited an aqueous solubility value of 4.95  $\mu\text{g/mL}$  ( $7.5 \times 10^{-6}$  M) at 25°C. Hesperidin did not demonstrate pH dependent solubility within the pH range of 1.2–9. However, solubility of hesperidin at pH values greater than 9 was significantly higher (data not shown) but was accompanied with degradation. These results are in agreement with the studies reported by Serra *et al.* wherein the pKa of hesperidin has been reported to be  $10 \pm 0.2$  for the two phenolic hydroxyl groups and greater than 11.5 for all of the alcoholic hydroxyl groups (21).

In an attempt to improve hesperidin's aqueous solubility, effect of ethanol, surfactants and HP- $\beta$ -CD, was evaluated. Ethanol and surfactants such as Tween 80 and TPGS (d-alpha-tocopheryl polyethylene glycol 1000 succinate) were ineffective. However, HP- $\beta$ -CD markedly improved hesperidin's solubility. Cyclodextrins are a group of cyclic oligosaccharides that have been shown to improve solubility of a multitude of poorly soluble compounds, through the formation of inclusion complexes. Among the different cyclodextrins available, HP- $\beta$ -CD has been reported to be safe for use in ocular preparations (26,27), even when used at concentrations as high as 45% (28).

A linear increase in aqueous solubility of hesperidin was observed with increasing concentrations of HP- $\beta$ -CD (Fig. 4 and Table II) suggesting formation of a 1:1 inclusion complex between hesperidin and HP- $\beta$ -CD. It is interesting to note that hesperidin's solubility was increased approximately 100-fold in the presence of 20% HP- $\beta$ -CD. The solubility limit of the



**Fig. 4.** Phase solubility of hesperidin in the presence of HP- $\beta$ -CD, at 25°C, following 24 h equilibration. Values are expressed as mean  $\pm$  SD ( $n=3$ ).

complex was not reached within the concentration range of HP- $\beta$ -CD used in this study. Stoichiometry, binding constant ( $K$ ) and aqueous saturation solubility ( $S_0$ ) were determined from a plot of solubility as a function of HP- $\beta$ -CD concentration using Eq. 4, according to the method proposed by Higuchi and Connors. Hesperidin binding constant was calculated to be  $625 \pm 78 \text{ M}^{-1}$  ( $R^2=0.975 \pm 0.023$ , slope= $0.0052 \pm 0.0006$ ).

$$K = \frac{\text{Slope}}{S_0(1 - \text{Slope})} \quad (4)$$

Further evidence of the formation of an inclusion complex was obtained from thermal and spectral analysis. The DSC thermograms are presented in Fig. 5. DSC scans of pure hesperidin showed an endothermic peak at 259°C, corresponding to the melting point of the compound. Physical mixture of the drug and HP- $\beta$ -CD, in a 1:1 molar ratio, also exhibited the endothermic peak associated with hesperidin. However, the peak was not observed in the complex, prepared by dissolving both the components in methanol (1:1 molar ratio) followed by evaporation. This suggests molecular encapsulation of drug inside the cyclodextrin cavity. FTIR scans complemented the DSC data (Fig. 6). Hesperidin spectra demonstrate a strong absorption band at  $1,644 \text{ cm}^{-1}$ , corresponding to its carbonyl stretching vibration. This characteristic carbonyl stretching vibration was shifted to

**Table I.** Solubility of Hesperidin as a Function of pH (200 mM Buffer Concentration) and in Water

pH	Saturation solubility ( $\mu\text{g/mL}$ )
1.21	4.15 $\pm$ 0.34
3.11	8.44 $\pm$ 0.47
5.12	5.96 $\pm$ 1.92
7.48	5.26 $\pm$ 0.31
9.11	8.93 $\pm$ 0.73
Water	4.93 $\pm$ 0.99

The solubility studies were carried out at 25°C for a period of 24 h. Values are expressed as mean  $\pm$  SD ( $n=3$ )

**Table II.** Aqueous Solubility of Hesperidin (25°C, 24 h Equilibration) in the Presence of Various Concentrations of HP- $\beta$ -CD

Concentration of HP- $\beta$ -CD (% w/v)	Hesperidin solubility ( $\mu\text{g/mL}$ )	Fold Increase in solubility
0	4.95 $\pm$ 0.99	
1	42.97 $\pm$ 4.28	9
2.5	83.34 $\pm$ 6.34	18
5	169.90 $\pm$ 25.36	37
7.5	219.03 $\pm$ 15.62	48
10	252.77 $\pm$ 8.81	55
15	348.55 $\pm$ 5.28	76
20	431.97 $\pm$ 0.43	95

Values are expressed as mean  $\pm$  SD ( $n=3$ )




Fig. 5. DSC thermograms of the pure hesperidin and HP- $\beta$ -CD, physical mixture of hesperidin and HP- $\beta$ -CD (1:1 molar ratio) and the complex.





Fig. 6. FTIR spectra of the HP- $\beta$ -CD, hesperidin and the complex.

1,652  $\text{cm}^{-1}$  in the complex and was much broader, suggesting the formation of complex. Thus, chemical, thermal and spectral analysis, taken together, strongly supports the formation of an inclusion complex.

Phase solubility studies pointed towards the formation of the complex in a 1:1 molar ratio, which is consistent with an earlier report by Tommasini *et al.* (29). However, the observed intrinsic solubility of hesperidin ( $7.5 \times 10^{-6}$  M) in the current study was less than the value ( $3.6 \times 10^{-5}$  M) reported by Tommasini *et al.* Also, the estimated binding constant in the previous study was  $60 \text{ M}^{-1}$ . The observed differences, between the earlier report and the current study, with respect to these two parameters, may be attributed to the experiment protocol. While Tommasini *et al.* sonicated the excess drug containing cyclodextrin solution for a period of 15 min and then allowed equilibration for a period of 4 days, in the current study sonication was not a part of the protocol and equilibration period allowed was only 24 h.

Hesperidin, a flavonoid glycoside, can be converted into its aglycone, hesperetin through chemical or enzymatic processes. Stability studies in aqueous solutions did not demonstrate any decrease in hesperidin content upto 2 months, the final time point tested, in the pH range and temperature conditions employed. The only exception was pH 9 samples. In this case, degradation rate constant and half-lives, at 25°C and 40°C were observed to be 0.03 and 0.15  $\text{day}^{-1}$ , and, 23 and 4.5 days, respectively (Fig. 7). This



**Fig. 7.** Stability of hesperidin in pH 9 buffer at 25°C and 40°C. Values are expressed as mean $\pm$ SD ( $n=3$ ).

signifies that hesperidin may undergo alkaline hydrolysis at higher pH and temperature conditions.


Hesperidin undergoes enzymatic degradation by beta-glucosidases to yield hesperetin. Literature reports suggest that beta-glucosidases are expressed in the ocular tissues, especially in the RPE (30,31). Ideally, one would like to maintain the drug in the unmetabolized form at the target tissue for maximizing therapeutic effect. With respect to hesperidin, however, both hesperidin and its aglycone hesperetin, are pharmacologically active. Even then, it is important to know the rate of generation of hesperetin, from hesperidin, in the ocular tissues as the two compounds would exhibit different pharmacokinetic profiles. For example, hesperetin is more lipophilic than hesperidin and is known to be a much better substrate of the efflux protein P-gp, which is also known to be expressed on the RPE (32). Consequently, conversion of hesperidin to hesperetin may impact therapeutic activity. Taking this into consideration, stability of hesperidin in ocular tissue homogenates was determined. Hesperetin generation, or decrease in hesperidin concentrations, in the homogenates was not observed even after 15 h. Further studies investigating generation of hesperetin in the ocular tissues *in vivo*, and their *in vivo* pharmacokinetic profile following topical and intravitreal administration, are in progress.

Oral hesperidin administration for ocular indications may not be very effective. Local delivery of hesperidin for ocular diseases may prove to be a much more viable option, compared to oral administration. To our knowledge, hitherto, permeability of hesperidin across ocular tissues has not been determined. In this study, ocular tissues isolated from New Zealand albino rabbits, a model widely used for ophthalmic drug delivery studies, were used to evaluate feasibility of penetration of hesperidin into the back-of-the eye following topical administration. The predicted Log P value of hesperidin was determined to be  $1.78\pm 0.72$  using ACD/I-Lab software, which indicated that the compound is fairly lipophilic. Diffusion studies were carried out for 3 h, to determine *in vitro* permeability coefficients across cornea, sclera and sclera/choroid/RPE. Stability studies of hesperidin in aqueous buffered solutions and tissue homogenates demonstrated that drug was stable in these matrices for the


entire duration of the diffusion experiments. Since hesperidin demonstrates poor aqueous solubility, 5% HP- $\beta$ -CD was incorporated in the transport buffer.

Trans-epithelial electrical resistance (TEER) was monitored (Multimeter, Agilent Technologies, USA) throughout the duration of the corneal permeation studies, 3 h, to evaluate the integrity of tissue in the presence of 5% HP- $\beta$ -CD. TEER values for corneas exposed to transport buffers with or without HP- $\beta$ -CD were found to be  $5\pm 0.3$  K $\Omega$ cm<sup>2</sup> throughout, demonstrating lack of any effect of HP- $\beta$ -CD on ocular tissue integrity at this concentration. The observed TEER is in agreement with previously reported TEER values for rabbit cornea (33). In addition, diffusion of [<sup>14</sup>C]mannitol, a paracellular marker, and [<sup>3</sup>H]diazepam, a transcellular marker, were also evaluated. The mean percent cumulative amount of the [<sup>14</sup>C]mannitol transported per hour across the cornea remained the same, for the duration of the experiment at  $1\pm 0.15$ . In case of diazepam also, mean percent cumulative amount of [<sup>3</sup>H]diazepam transported per hour across the cornea remained steady at  $1.62\pm 0.04$ . These results taken together, demonstrate that integrity and viability of the corneal tissues are maintained during the experimental protocol.

Mean cumulative amount of hesperidin transported across ocular tissues as a function of time is depicted in Fig. 8 and the permeability coefficients have been presented in Fig. 9. Steady state diffusion was achieved within 5 min.



**Fig. 8.** Mean cumulative amount of hesperidin transported across ocular tissues as a function of time. Values are expressed as mean $\pm$ SD ( $n=4$ ).



**Fig. 9.** Permeability (cm/s) of hesperidin across various ocular tissues. A–B denotes permeation in the apical to basolateral direction. S–R and R–S denotes permeation in the sclera to RPE direction and RPE to sclera direction. Values are expressed as mean ± SD ( $n=4$ ).

Less than 2% decrease in hesperidin concentration in the donor solution was observed during the total time course of the experiments signifying maintenance of sink conditions.

Hesperidin's permeability across the rabbit cornea was  $1.11 \pm 0.86 \times 10^{-6}$  cm/s consistent with other compounds with similar LogP values (34). Although, P-gp has been reported to play a important role in transcorneal drug absorption (32), corneal permeability of hesperidin in the apical to basolateral (A–B;  $1.11 \pm 0.86 \times 10^{-6}$  cm/s) and basolateral to apical (B–A;  $1.16 \pm 0.05 \times 10^{-6}$  cm/s) directions did not differ statistically, indicating lack of involvement of any carrier-mediated process (efflux or influx) in the corneal permeation process, at the concentration studied. These results are consistent with an earlier study by Kobayashi *et al.* (20) with Caco-2 cell monolayers demonstrating similar hesperidin permeability in the A–B and B–A directions. The authors concluded that hesperidin permeates through paracellular route and absence of active transport process. Moreover, hesperidin behaves as a neutral molecule in the pH range of 1–10 (21) indicating lack of involvement of any anion or cation transporters.

Transport studies across sclera and sclera/choroid/RPE were carried out using Valia–Chien cells (PermeGear, Inc. USA). To our knowledge, these cells are being adapted for studying permeability across the RPE for the first time. The scleral tissue tends to fold-up into its natural elliptical shape while mounting on the regular flat face cells. This creates mounting problems, especially the risk of damaging the RPE layer. On the other hand, it is very easy to mount the sclera/choroid/RPE tissue on the Valia–Chien cells. To check the validity of the new experimental set up, acyclovir (ACV) transport across sclera with RPE was carried out from the S to R (sclera to RPE) direction. The observed permeability was  $2.5 \times 10^{-6}$  cm/s. Although there are no prior reports for trans-RPE permeability of ACV, Kansara *et al.* (35) reported that the permeability of ganciclovir (GCV) in the S to R direction was  $1.61 \times 10^{-6}$  cm/s. GCV and ACV are very similar structurally, and with respect to their physicochemical characteristics. Moreover, the permeability of ACV and GCV across the rabbit cornea are reported to be very similar ( $3.5 \times 10^{-6}$  and  $4.1 \times 10^{-6}$  cm/s, respectively) (36,37),

indicating that their membrane permeation characteristics are also comparable. The close approximation of the permeability of ACV obtained using the Valia-Chien cells with that of GCV in the Franz diffusion cells, indicate that the RPE structure was intact during the experimental protocol. Moreover, the mean percent cumulative amount of [<sup>14</sup>C] mannitol and [<sup>3</sup>H]diazepam transported per hour across the sclera/choroid/RPE tissues were  $0.1 \pm 0.04$  and  $0.08 \pm 0.02$ , respectively, similar to the values reported by Kansara *et al.* (35). The above results indicate that sclera/choroid/RPE tissue maintains its integrity during the experimental protocol.

Permeability of hesperidin across the sclera alone ( $10.2 \pm 2.1 \times 10^{-6}$  cm/s) was almost tenfold higher than that across sclera with RPE (Figs. 8 and 9) and that across the cornea. These results thus substantiate the concept that RPE presents a significant barrier to the transscleral diffusion process following systemic as well as topical administration. However, topical instillation should generate significantly higher concentration gradients across the RPE and thus higher retinal hesperidin concentrations.

The barrier properties of the RPE may be as a result of efflux pump involvement or high lipophilicity of the therapeutic agent. The RPE is reported to express P-gp (32), which can modulate drug clearance from the vitreous humor. To delineate the role of efflux mechanisms on trans-RPE drug delivery, permeability of hesperidin across RPE in both directions i.e. sclera→choroid→RPE (S–R) and RPE→choroid→sclera (R–S) was measured and were found to be  $0.82 \pm 0.68 \times 10^{-6}$  cm/s and  $1.52 \pm 0.78 \times 10^{-6}$  cm/s, respectively (Figs. 8 and 9). The difference in permeability in the S–R and R–S directions, under the experimental conditions employed, was statistically insignificant suggesting lack of any efflux mechanism.

In conclusion, results from this study suggest that hesperidin solubility can be markedly improved by complexation with HP- $\beta$ -CD and that hesperidin exhibits sufficient chemical and enzymatic stability in aqueous solutions and biological matrices, respectively. Additionally, ocular tissue permeation characteristics of hesperidin are not limited by efflux mechanisms. Thus, topical delivery of hesperidin in the form of ophthalmic solutions/suspensions appears feasible. A pH range of 6.5–8.5 is considered to be optimal for ophthalmic formulations. Considering the favorable permeability, solubility and stability profiles, it would be reasonable to formulate hesperidin based ophthalmic solutions at pH 7.4. Further investigation into penetration of hesperidin into the back-of-the eye ocular tissues, following topical and systemic administration is warranted.

#### ACKNOWLEDGEMENT

This project was supported by NIH grant numbers P20RR021929, from the National Center for Research Resources, and EY018426-01 from the National Eye Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Eye Institute, National Institutes of Health.



## REFERENCES

- A. Ryskulova, K. Turczyn, D. M. Makuc, M. F. Cotch, R. J. Klein, and R. Janiszewski. Self-reported age-related eye diseases and visual impairment in the United States: results of the 2002 national health interview survey. *Am. J. Public Health*. **98**:454–461 (2008) doi:10.2105/AJPH.2006.098202.
- J. L. Wilkinson-Berka. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cyclooxygenase-2 and nitric oxide. *Curr. Pharm. Des.* **10**:3331–3348 (2004) doi:10.2174/1381612043383142.
- X. R. Chiou G.C. Effects of some natural flavonoids on retinal function recovery after ischemic insult in the rat. *J. Ocular Pharmacol. Therap.* **20**:107–113 (2004) doi:10.1089/108076804773710777.
- A. Garg, S. Garg, L. J. Zaneveld, and A. K. Singla. Chemistry and pharmacology of the citrus bioflavonoid hesperidin. *Phytother. Res.* **15**:655–669 (2001) doi:10.1002/ptr.1074.
- J. M. Beiler, and G. J. Martin. Inhibition of hyaluronidase action by derivatives of hesperidin. *J. Biol. Chem.* **174**:31–34 (1948).
- J. Zhang, R. A. Stanley, L. D. Melton, and M. A. Skinner. Inhibition of lipid oxidation by phenolic antioxidants in relation to their physicochemical properties. *Pharmacologyonline*. **1**:180–189 (2007).
- A. Hirata, Y. Murakami, M. Shoji, Y. Kadoma, and S. Fujisawa. Kinetics of radical-scavenging activity of hesperetin and hesperidin and their inhibitory activity on COX-2 expression. *Anticancer Res.* **25**:3367–3374 (2005).
- S. P. Ayalasoamayajula, A. C. Amrite, and U. B. Kompella. Inhibition of cyclooxygenase-2, but not cyclooxygenase-1, reduces prostaglandin E2 secretion from diabetic rat retinas. *Eur. J. Pharmacol.* **498**:275–278 (2004) doi:10.1016/j.ejphar.2004.07.046.
- E. M. Galati, M. T. Monforte, S. Kirjavainen, A. M. Forestieri, A. Trovato, and M. M. Tripodo. Biological effects of hesperidin, a citrus flavonoid. (Note I): antiinflammatory and analgesic activity. *Farmaco*. **40**:709–712 (1994).
- M. T. Monforte, A. Trovato, S. Kirjavainen, A. M. Forestieri, E. M. Galati, and R. B. Lo Curto. Biological effects of hesperidin, a citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. *Farmaco*. **50**:595–599 (1995).
- E. M. Galati, A. Trovato, S. Kirjavainen, A. M. Forestieri, A. Rossitto, and M. T. Monforte. Biological effects of hesperidin, a citrus flavonoid. (Note III): antihypertensive and diuretic activity in rat. *Farmaco*. **51**:219–221 (1996).
- T. Tanaka, H. Makita, M. Ohnishi, H. Mori, K. Satoh, A. Hara, T. Sumida, K. Fukutani, T. Tanaka, and H. Ogawa. Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis in rats by flavonoids diosmin and hesperidin, each alone and in combination. *Cancer Res.* **57**:246–252 (1997).
- T. Tanaka, H. Makita, K. Kawabata, H. Mori, M. Kakumoto, K. Satoh, A. Hara, T. Sumida, T. Tanaka, and H. Ogawa. Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. *Carcinogenesis*. **18**:957–965 (1997) doi:10.1093/carcin/18.5.957.
- B. Ameer, R. A. Weintraub, J. V. Johnson, R. A. Yost, and R. L. Rouseff. Flavanone absorption after naringin, hesperidin, and citrus administration. *Clin. Pharmacol. Ther.* **60**:34–40 (1996) doi:10.1016/S0009-9236(96)90164-2.
- A. Gil-Izquierdo, M. I. Gil, F. A. Tomas-Barberan, and F. Ferreres. Influence of industrial processing on orange juice flavanone solubility and transformation to chalcones under gastrointestinal conditions. *J. Agric. Food Chem.* **51**:3024–3028 (2003) doi:10.1021/jf020988r.
- T. H. Tsai, and M. C. Liu. Determination of extracellular hesperidin in blood and bile of anaesthetized rats by microdialysis with high-performance liquid chromatography: a pharmacokinetic application. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* **806**:161–166 (2004) doi:10.1016/j.jchromb.2004.03.047.
- Y. Mitsunaga, H. Takanaga, H. Matsuo, M. Naito, T. Tsuruo, H. Ohtani, and Y. Sawada. Effect of bioflavonoids on vincristine transport across blood-brain barrier. *Eur. J. Pharmacol.* **395**:193–201 (2000) doi:10.1016/S0014-2999(00)00180-1.
- M. Ofer, S. Wolfram, A. Koggel, H. Spahn-Langguth, and P. Langguth. Modulation of drug transport by selected flavonoids: involvement of P-gp and OCT? *Eur. J. Pharm. Sci.* **25**:263–271 (2005).
- V. M. Breinholt, E. A. Offord, C. Brouwer, S. E. Nielsen, K. Brosen, and T. Friedberg. *In vitro* investigation of cytochrome P450-mediated metabolism of dietary flavonoids. *Food Chem. Toxicol.* **40**:609–616 (2002) doi:10.1016/S0278-6915(01)00125-9.
- S. Kobayashi, S. Tanabe, M. Sugiyama, and Y. Konishi. Trans-epithelial transport of hesperetin and hesperidin in intestinal Caco-2 cell monolayers. *Biochim. Biophys. Acta.* **1778**:33–41 (2008) doi:10.1016/j.bbame.2007.08.020.
- H. Serra, T. Mendes, M. R. Bronze, and A. L. Simplicio. Prediction of intestinal absorption and metabolism of pharmacologically active flavones and flavanones. *Bioorg. Med. Chem.* **16**:4009–4018 (2008).
- C. Manach, C. Morand, A. Gil-Izquierdo, C. Bouteloup-Demange, and C. Remesy. Bioavailability in humans of the flavanones hesperidin and naringin after the ingestion of two doses of orange juice. *Eur. J. Clin. Nutr.* **57**:235–242 (2003) doi:10.1038/sj.ejcn.1601547.
- A. K. Mitra, S. Macha, and P. M. Hughes. *Ophthalmic Drug Delivery Systems*. Marcel Dekker, New York, 2003.
- M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal. Biochem.* **72**:248–254 (1976) doi:10.1016/0003-2697(76)90527-3.
- N. M. Holekamp, M. A. Thomas, and A. Pearson. The safety profile of long-term, high-dose intraocular corticosteroid delivery. *Am. J. Ophthalmol.* **139**:421–428 (2005) doi:10.1016/j.ajo.2004.09.046.
- T. Jansen, B. Xhonneux, J. Mesens, and M. Borgers. Beta-cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effects on rabbit corneal epithelium. *Lens Eye Toxic. Res.* **7**:459–468 (1990).
- P. Saarinen-Savolainen, T. Jarvinen, K. Araki-Sasaki, H. Watanabe, and A. Urtti. Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line. *Pharm. Res.* **15**:1275–1280 (1998) doi:10.1023/A:1011956327987.
- T. Loftsson, and T. Jarvinen. Cyclodextrins in ophthalmic drug delivery. *Adv. Drug Deliv. Rev.* **36**:59–79 (1999) doi:10.1016/S0169-409X(98)00055-6.
- S. Tommasini, M. L. Calabro, R. Stancanelli, P. Donato, C. Costa, S. Catania, V. Villari, P. Ficarra, and R. Ficarra. The inclusion complexes of hesperetin and its 7-rhamnoglucoside with (2-hydroxypropyl)-beta-cyclodextrin. *J. Pharm. Biomed. Anal.* **39**:572–580 (2005) doi:10.1016/j.jpba.2005.05.009.
- D. K. Wilcox. Extracellular release of acid hydrolases from cultured retinal pigmented epithelium. *Invest. Ophthalmol. Vis. Sci.* **28**:76–82 (1987).
- A. J. Adler. Selective presence of acid hydrolases in the interphotoreceptor matrix. *Exp. Eye Res.* **49**:1067–1077 (1989) doi:10.1016/S0014-4835(89)80027-2.
- E. Mannerman, K. S. Vellonen, and A. Urtti. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. *Adv. Drug Deliv. Rev.* **58**:1136–1163 (2006) doi:10.1016/j.addr.2006.07.024.
- W. S. Marshall, and S. D. Klyce. Cellular and paracellular pathway resistances in the “tight” Cl<sup>-</sup>-secreting epithelium of rabbit cornea. *J. Membr. Biol.* **73**:275–282 (1983) doi:10.1007/BF01870542.
- M. R. Prausnitz, and J. S. Noonan. Permeability of cornea, sclera, and conjunctiva: a literature analysis for drug delivery to the eye. *J. Pharm. Sci.* **87**:1479–1488 (1998) doi:10.1021/js9802594.
- V. Kansara, Y. Hao, and A. K. Mitra. Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina. *J. Ocul. Pharmacol. Ther.* **23**:321–334 (2007) doi:10.1089/jop.2006.0150.
- S. Majumdar, K. Hippalgaonkar, and M. A. Repka. Effect of chitosan, benzalkonium chloride and ethylenediaminetetraacetic acid on permeation of acyclovir across isolated rabbit cornea. *Int. J. Pharm.* **348**:175–178 (2008) doi:10.1016/j.ijpharm.2007.08.017.
- S. Majumdar, Y. E. Nashed, K. Patel, R. Jain, M. Itahashi, D. M. Neumann, J. M. Hill, and A. K. Mitra. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: *in vitro* and *in vivo* evaluations. *J. Ocul. Pharmacol. Ther.* **21**:463–474 (2005) doi:10.1089/jop.2005.21.463.